The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

Findings showed tocilizumab-anoh had comparable efficacy ... Avtozma is supplied as a preservative-free solution in 20mg/mL single-dose vials (80mg/4mL, 200mg/10mL, 400mg/20mL) for intravenous ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be ...

Rheumatoid factor (RF) levels above a normal range can indicate autoimmune conditions, such as rheumatoid arthritis (RA). Rheumatoid factor (RF) is an immune system protein that attacks healthy ...

The FDA has approved Celltrion’s similar of Genentech’s Actemra (tocilizumab). Celltrion’s Avtozma (tocilizumab-anoh) will be available as both an intravenous (IV) and subcutaneous (SC) formulations ...

Roche’s Actemra may help fight pandemic after all with phase 3 trial results showing it cut the chances of COVID-19 patients, mainly from higher risk minority ethnic backgrounds with pneumonia ...

Celltrion’s Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and ...

Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA). Different parts of the immune system have been targeted by monoclonal ...